Welcome to our dedicated page for Sol Gel Technolg news (Ticker: SLGL), a resource for investors and traders seeking the latest updates and insights on Sol Gel Technolg stock.
Sol-Gel Technologies Ltd. (NASDAQ: SLGL) is a dermatology company whose news flow centers on clinical trial progress, regulatory milestones, licensing transactions and financial updates related to its topical drug products and pipeline. The company developed TWYNEO, a fixed-dose combination cream for acne vulgaris, and EPSOLAY, a benzoyl peroxide cream for inflammatory lesions of rosacea, and continues to report on ex-U.S. approvals and commercialization agreements for these products.
Recent Sol-Gel news highlights include updates on its pivotal Phase 3 clinical trial of SGT-610 (patidegib gel 2%) for Gorlin syndrome, including completion of patient enrollment and expectations for future top-line results. The company also issues releases on exploratory work to extend SGT-610 into high-frequency basal cell carcinoma and on compassionate-use cases in patients with PTCH1-mutated lesions. For SGT-210, a topical erlotinib candidate for Darier disease and other rare hyperkeratinization disorders, Sol-Gel has reported on Phase 1b proof-of-concept data, trial design decisions and plans for feasibility studies in additional indications.
Investors following SLGL news will also find announcements on Health Canada’s approval of EPSOLAY, new license agreements with partners such as Searchlight Pharma, Viatris and regional distributors, and a product purchase agreement with a subsidiary of Mayne Pharma for U.S. rights to EPSOLAY and TWYNEO. Periodic financial results releases provide detail on revenue from licensing and royalties, research and development spending on SGT-610 and SGT-210, cash runway expectations and capital market developments such as the company’s reverse share split and Nasdaq listing status.
This news page aggregates these company-issued updates and related coverage, making it easier to track Sol-Gel’s clinical, regulatory and commercial milestones over time for its dermatology portfolio and rare disease pipeline.
Sol-Gel Technologies, a clinical-stage dermatology firm, will present a company overview at two upcoming virtual investor conferences. The first is the Jefferies Healthcare Conference, scheduled for June 1, 2021, where CEO Dr. Alon Seri-Levy will speak at 8:30 am EDT. The second is the Raymond James Human Health Innovation Conference on June 22, 2021, at 10:00 am EDT. The company focuses on developing topical treatments for skin diseases, with NDA submissions for two products pending FDA review. Recordings of the presentations will be available on their website.
Sol-Gel Technologies (NASDAQ: SLGL) announced its Q1 2021 financial results, reporting revenue of $0.7 million and a loss of $4.1 million, down from a $7.1 million loss in Q1 2020. The company is in advanced negotiations for the commercialization of EPSOLAY® and TWYNEO® with PDUFA goal dates of April 26, 2021, and August 1, 2021, respectively. R&D expenses decreased to $2.5 million, primarily due to reduced clinical trial costs. Sol-Gel has $34.2 million in cash and equivalents expected to sustain operations into Q3 2022.
Sol-Gel Technologies (NASDAQ: SLGL) has provided an update on its EPSOLAY® (benzoyl peroxide) 5% topical cream, aimed at treating inflammatory lesions of rosacea. Initially scheduled for FDA action by April 26, 2021, the process has been delayed due to the COVID-19 pandemic impacting pre-approval inspections. The FDA confirmed that it could not proceed with the NDA until an inspection is conducted. Sol-Gel is actively following up with the FDA to schedule this inspection, as it remains crucial for the product's approval.
Sol-Gel Technologies (NASDAQ: SLGL) reported FY 2020 revenue of $8.8 million, driven largely by collaborations with Perrigo. The company achieved significant milestones, with FDA accepting NDAs for Epsolay and Twyneo, scheduled for PDUFA dates of April 26 and August 1, 2021, respectively. However, Sol-Gel incurred a net loss of $29.3 million, worsening from $24.6 million in 2019. Cash and securities totaled $50.2 million, expected to fund operations through Q3 2022. Operational plans include partnering for commercialization to enhance market capture.
Sol-Gel Technologies (NASDAQ: SLGL), a dermatology-focused clinical-stage company, announced its participation in upcoming virtual investor conferences. CEO Dr. Alon Seri-Levy will speak at the Raymond James Institutional Investors Conference on March 1, 2021, at 8:20 AM ET, while CFO Gilad Mamlok will present at the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. A replay of the H.C. Wainwright presentation will be available on the company’s website for 30 days. The company continues to advance its pipeline of topical treatments for skin diseases.
Sol-Gel Technologies (NASDAQ: SLGL), a clinical-stage dermatology firm, announced its participation in two upcoming virtual investor conferences. Dr. Alon Seri-Levy, CEO, will present at the Solebury Trout 2021 Virtual Investor Conference from January 11-15, 2020, with on-demand access available. Additionally, CFO Gilad Mamlok will speak at the H.C. Wainwright BioConnect 2021 Virtual Conference from January 11-14, 2020, accessible to participants. Sol-Gel is focused on developing topical drugs for skin diseases, including treatments for acne and rosacea.
Sol-Gel Technologies (NASDAQ: SLGL) reported third-quarter 2020 revenues of $2.1 million, driven by generic product sales, with expectations of a revenue decrease due to increased competition. The FDA has accepted the New Drug Application (NDA) for Epsolay, targeting rosacea, with a PDUFA goal date of April 26, 2021. Additionally, an NDA for Twyneo has been submitted for acne treatment. The company reported a net loss of $8.6 million and has $57.3 million in cash and marketable securities, sufficient to fund operations through the third quarter of 2021.
Sol-Gel Technologies (NASDAQ: SLGL) announced its participation in two upcoming virtual investor conferences. The first is the H.C. Wainwright 6th Annual Israel Conference on November 12, 2020, at 8:30 AM ET, featuring CEO Dr. Alon Seri-Levy. The second is the Jefferies Virtual London Healthcare Conference on November 18, 2020, at 5:00 PM GMT, with several executives, including CFO Gilad Mamlok. Webcasts of the presentations will be accessible on the company’s website.
Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) will announce its third quarter 2020 financial results on November 12, 2020, at 7:05 AM ET. The company is a clinical-stage dermatology firm that specializes in developing branded and generic topical products for skin diseases. Their innovative microencapsulation technology is being used for products such as Twyneo and Epsolay, which are under investigation for acne vulgaris and papulopustular rosacea, respectively. Other pipeline projects include SGT-210, tapinarof, and roflumilast.
Sol-Gel Technologies (NASDAQ: SLGL) announced the FDA's acceptance of its New Drug Application (NDA) for Epsolay®, a topical cream targeting inflammatory lesions in rosacea. The PDUFA goal date is set for April 26, 2021, which could make Epsolay the first FDA-approved single-agent benzoyl peroxide prescription product. Results from Phase 3 trials, involving 733 patients, showed significant improvements in treatment outcomes compared to the vehicle. The adverse reactions were mostly mild to moderate, indicating a favorable safety profile.
FAQ
What is the current stock price of Sol Gel Technolg (SLGL)?
What is the market cap of Sol Gel Technolg (SLGL)?
